A Study of Belzutifan (MK-6482) in Combination with Palbociclib Versus Belzutifan Monotherapy in Participants with Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Trial Identifier: 6482-024
Sponsor: MSD
Start Date: August 2022
Primary Completion Date: September 2028
Study Completion Date: September 2028
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary – English
Protocol Plain Language Summary – English

Trial Locations

Country Location
Australia, New South Wales Macquarie University, New South Wales, Australia, 2109
Israel, N/A Haifa, N/A, Israel, 3109601
United States, DC Washington, DC, United States, 20007
United States, MA Boston, MA, United States, 02215
United States, UT Salt Lake City, UT, United States, 84112